Biosimilar Antibodies

ALT-100 is a humanized IgG1 monoclonal antibody specifically designed to target NAMPT (Nicotinamide phosphoribosyltransferase). This antibody is engineered from the human IgG1 subclass and is suitable for various immunological applications where NAMPT is implicated, including cancer research and inflammatory diseases. For accurate experimental controls, it is recommended to use Human IgG1 kappa Isotype Control.

Devextinetug (IXT-M200) is a chimeric monoclonal antibody of the IgG2κ subtype, derived from mouse sources, specifically targeting methamphetamine molecules. This antibody is engineered for high specificity and affinity in binding methamphetamine, making it an ideal tool for research studies focused on the detection and neutralization of this compound in various biological systems.

Sofituzumab (MMUC 1206A) is a recombinant, humanized V-kappa antibody targeting MUC16. This monoclonal antibody is designed for high specificity and affinity in binding to the MUC16 antigen, making it a valuable tool for research into cancer diagnostics and therapeutics where MUC16 is a relevant biomarker.

Izenivetmab (ZTS-00075623) is a caninized monoclonal antibody of the IgG2κ isotype, specifically targeting nerve growth factor beta (NGFB). This therapeutic antibody is designed for use in canine models, facilitating the study of NGFB's role in various biological processes and potential therapeutic interventions.

Sudubrilimab (HS636) is an IgG1-kappa monoclonal antibody targeting PD-L1. This antibody is uniquely engineered with a fusion to the C-terminus of the heavy chain incorporating a TGF-β1 receptor II ectodomain (TGFBR2-ECD). This design enables Sudubrilimab to simultaneously inhibit the PD-1/PD-L1 interaction and modulate TGF-β activity, effectively countering the immunosuppressive effects within the tumor microenvironment. This dual functionality makes it a valuable tool for research into cancer immunotherapy mechanisms and potential therapeutic interventions.

ATH3G10 is a fully human monoclonal antibody specifically designed to bind to oxidized phospholipids (OxPL). This antibody is engineered for high specificity and affinity, making it an ideal tool for research focused on oxidative stress, lipid oxidation, and related pathophysiological conditions. ATH3G10 is suitable for a variety of applications, including ELISA, Western blotting, and immunohistochemistry, facilitating detailed studies in cardiovascular diseases, inflammation, and other OxPL-associated disorders.

Evalstotug is a human IgG1 κ monoclonal antibody targeting CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4). For accurate experimental control, it is recommended to use Human IgG1 kappa isotype control.

Tecotabart is a humanized IgG1κ monoclonal antibody that specifically targets Claudin 18 (CLDN18). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

VRC-01 is a fully human monoclonal antibody of the IgG1 subclass that specifically targets the gp120 envelope glycoprotein of HIV-1. This antibody inhibits viral entry into host cells by emulating the binding mechanism of the CD4 receptor with the HIV-1 gp120 envelope glycoprotein, thereby blocking the virus's ability to infect cells. For experimental control purposes, Human IgG1 kappa, Isotype Control, is recommended. VRC-01 serves as a critical tool in the study of HIV pathogenesis and the development of therapeutic strategies against HIV infection.

The Anti-CD4 Antibody (TRX1) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the CD4 receptor, a critical molecule involved in the immune response. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 145 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended.

Livmoniplimab (ABBV-151) is a monoclonal antibody targeting the GARP/TGF-β1 complex, effectively inhibiting the release of active transforming growth factor-beta 1 (TGF-β1). Demonstrating significant anti-tumor activity in murine models of colon cancer, Livmoniplimab is primarily utilized in research focused on locally advanced or metastatic solid tumors. This antibody serves as a crucial tool in the investigation of TGF-β1's role in tumor microenvironments and cancer progression, offering potential insights into therapeutic strategies for solid tumors.

The Anti-TNFRSF21/DR6/CD358 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the TNFRSF21/DR6/CD358 antigen, a member of the tumor necrosis factor receptor superfamily involved in various cellular processes including apoptosis and inflammation. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and exhibits a molecular weight of approximately 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Adecatumumab (MT201) is a fully human monoclonal antibody of the IgG1 isotype designed to specifically target human EpCAM (Epithelial Cell Adhesion Molecule). This antibody is recognized for its broad expression across various adenocarcinomas. Importantly, the efficacy of Adecatumumab is independent of the K-Ras mutation status, making it a versatile tool in the research of carcinomas where EpCAM is a critical factor.

Certolizumab pegol is a recombinant, polyethylene glycolylated antigen-binding fragment derived from a humanized monoclonal antibody. It selectively targets and neutralizes tumor necrosis factor-alpha (TNF-α), making it highly relevant for studies in rheumatoid arthritis and Crohn's disease. This specificity for TNF-α provides a critical tool for researchers investigating the pathophysiology and therapeutic interventions of these inflammatory disorders.

Epratuzumab, designated as hLL 2, is a humanized IgG1 monoclonal antibody targeting CD22, a cell surface antigen expressed predominantly on B cells. This antibody functions not only as an immunomodulatory agent but also as a tumor-imaging agent due to its specific binding to CD22. Epratuzumab has demonstrated the ability to induce phosphorylation of CD22, which plays a critical role in the modulation of B cell signaling and function. The primary applications of Epratuzumab have been in the study of non-Hodgkin’s lymphomas (NHL) and various autoimmune diseases, where it has shown potential in modulating immune responses and providing diagnostic imaging insights.

Bempikibart (ADX-914) is a humanized monoclonal antibody targeting the interleukin-7 receptor alpha (IL-7Rα). Designed for research purposes, it is utilized primarily in the study of inflammatory processes. This antibody may serve as a valuable tool in investigating the role of IL-7Rα in immune response modulation and inflammation.

Anumigilimab (CSL-324) is a human IgG4 monoclonal antibody targeting the granulocyte colony-stimulating factor (G-CSF) receptor. This antibody is designed to modulate immune responses by increasing the recruitment of neutrophils to sites of inflammation. Anumigilimab is primarily utilized in research focused on the mechanisms of neutrophil mobilization and the inflammatory response, offering potential insights into therapeutic strategies for diseases characterized by acute or chronic inflammation.

Ongericimab (JS002) is a humanized monoclonal antibody targeting PCSK9, designed to effectively lower lipid levels. This antibody is specifically developed for research applications focusing on hypercholesterolemia and hyperlipidemia, providing a valuable tool for investigating the regulation of cholesterol metabolism and assessing potential therapeutic strategies for lipid disorders.

The Anti-B7-H3/CD276 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells specifically targeting the B7-H3/CD276 antigen. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 145 kDa. For experimental control purposes, the Human IgG1 kappa Isotype Control is recommended as a suitable reference standard. This antibody is essential for studies focusing on the role of the B7-H3/CD276 pathway in immune regulation and cancer immunotherapy.

Crizanlizumab is a monoclonal antibody that targets P-selectin, effectively inhibiting its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). By blocking this interaction, Crizanlizumab plays a crucial role in preventing vaso-occlusive crises (VOCs), making it a valuable tool for the study and research of sickle cell disease pathophysiology and therapeutic interventions.

CLN-619 is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target MICA (MHC class I polypeptide-related sequence A). This antibody is composed of a human immunoglobulin G1 (huIgG1) heavy chain and a human kappa (huκ) light chain, with an approximate molecular weight of 146.06 kDa. For isotype control experiments, Human IgG1 kappa, Isotype Control is recommended. This specificity and structure make CLN-619 ideal for detailed studies on MICA's role in immune response and its implications in various pathological conditions.

Crovalimab (SKY59; RO7112689) is a novel humanized monoclonal antibody designed to target complement component 5 (C5) in a pH-dependent manner. It exhibits dissociation constants (K_D) of 15.2 nM at pH 7.4 and 16.8 μM at pH 5.8, reflecting its pH-responsive binding affinity. Additionally, Crovalimab demonstrates strong binding to human FcRn with a K_D of 17 μM at pH 6.0. This antibody effectively blocks the cleavage of C5 by C5 convertase and inhibits the activity of a specific C5 variant characterized by the p.Arg885His mutation. Furthermore, Crovalimab significantly inhibits the formation of the terminal complement complex C5b-9 across all three complement pathways: classical, lectin, and alternative. Due to these properties, Crovalimab is of significant interest for research into paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases, offering potential insights into novel therapeutic approaches.

Arumakimig is a bispecific humanized antibody designed to target and neutralize both interleukin-18 (IL-18) and interleukin-1β (IL-1β). This dual specificity makes it an invaluable tool for research focused on inflammation and immune response modulation. Arumakimig is particularly suited for studies investigating the pathophysiology of diseases characterized by excessive or dysregulated inflammation, offering insights into potential therapeutic interventions.

Evunzekibart (ATOR-1017) is a 4-1BB agonist that functions conditionally through Fc-γ receptor engagement, classified as an IgG4-type antibody. This biologic is designed to activate immune responses against cancer cells either as a standalone treatment or in synergy with anti-PD1 therapies, enhancing its potential for anticancer efficacy.

Pamvatamig is a human IgG4 κ monoclonal antibody that targets both EGFR and MET receptors. For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is designed for the study of signal transduction pathways and may be useful in research focused on cancer biology where EGFR and MET play critical roles.

Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) designed to simultaneously target human CD33 and human CD3 antigens. This unique configuration facilitates the recruitment and activation of T cells against CD33-expressing cells, making it a valuable tool in the study of acute myeloid leukemia (AML). Vixtimotamab's dual targeting mechanism offers a promising approach for elucidating the interactions between immune cells and leukemia cells, providing significant insights into therapeutic strategies for AML.

Nimotuzumab is a humanized IgG1 monoclonal antibody engineered to target the epidermal growth factor receptor (EGFR) with a dissociation constant (K_D) of 0.21 nM. This antibody specifically binds to the extracellular domain of EGFR, effectively inhibiting the receptor's interaction with its natural ligands. Nimotuzumab exhibits potent antitumor activity, primarily through the induction of antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This mechanism facilitates the targeted destruction of tumor cells, underscoring its utility in oncological research and therapeutic applications.

Rivabazumab is a recombinant monoclonal antibody specifically targeting the PcrV protein of Pseudomonas aeruginosa. This antibody is designed for the precise detection and neutralization of the PcrV component, which plays a critical role in the pathogenicity of Pseudomonas aeruginosa by facilitating the injection of toxic effector proteins into host cells. Rivabazumab is utilized extensively in research focused on bacterial infection mechanisms, vaccine development, and therapeutic interventions against Pseudomonas aeruginosa.

Laprituximab (J2898A) is a humanized IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). This antibody serves as a precursor for the synthesis of the antibody-drug conjugate (ADC) IMGN289, utilized in targeted cancer therapy research.

Enfortumab is a humanized antibody targeting Nectin-4, suitable for conjugation with the potent microtubule disruptor, monomethyl auristatin E (MMAE), to form the antibody-drug conjugate (ADC) Enfortumab vedotin. This ADC is specifically designed for research into locally advanced and metastatic urothelial carcinoma, offering a targeted approach to study the therapeutic efficacy and mechanism of action in these cancer models.

Lucatumumab (HCD122) is a fully human monoclonal antibody that functions as an antagonist to CD40, effectively blocking CD40/CD40L-mediated signaling pathways. This antibody is proficient in mediating antibody-dependent cell-mediated cytotoxicity (ADCC), facilitating the clearance of tumor cells. It is primarily utilized in research focused on refractory lymphomas, chronic lymphocytic leukemia (CLL), and multiple myeloma, offering significant insights into therapeutic strategies for these malignancies.

Cemiplimab, a monoclonal IgG4 antibody, exhibits high affinity for the programmed death receptor-1 (PD-1). It effectively blocks the PD-1/PD-L1 interaction, which is critical in mediating T-cell suppression. This antibody is predominantly utilized in the study of squamous cell carcinoma of the skin, providing a valuable tool for investigating immune checkpoint blockade therapies in cancer research.

LY3022856 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Vascular Endothelial Growth Factor Receptor 3 (VEGFR3), also known as FLT4. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 146.18 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended. This antibody is suitable for use in research applications focusing on the role of VEGFR3 in angiogenesis and lymphangiogenesis.

Trevotamig is a bispecific antibody designed to target EPCAM and CD3E. This dimer-type antibody is engineered from the H-γ1_L-κ-scFvhl framework, offering precise dual specificity. It facilitates targeted immunotherapy by engaging both tumor cells and T-cells, making it a valuable tool for research in cancer immunology and therapeutic development.

Bexmarilimab (FP-1305) is a humanized IgG4 monoclonal antibody that targets CLEVER-1 with a high affinity, demonstrated by an IC50 value of 4.51 nM. This antibody is effective in inducing a phenotypic switch from M2 to M1 in tumor-associated macrophages, a process critical for modulating the immune environment in oncological research. Bexmarilimab is primarily utilized in the study of cancer immunotherapy and tumor microenvironment dynamics.

Besufetamig is a bispecific monoclonal antibody designed to simultaneously target the programmed cell death protein 1 (PD-1) and the CD3ε chain. This innovative antibody modulates immune cell activity, demonstrating both immunosuppressive and antineoplastic properties. It is particularly valuable in cancer research, offering potential insights into novel immunotherapeutic strategies.

Solanezumab is a humanized monoclonal IgG1 antibody that specifically targets the mid-domain of the amyloid-β (Aβ) peptide. This antibody is designed for use in Alzheimer’s disease research, focusing on the pathological mechanisms associated with Aβ aggregation and plaque formation. Solanezumab's specificity and mode of action make it a valuable tool for investigating the potential therapeutic interventions in Alzheimer’s disease pathology.

Prezalumab (AMG 557) is a monoclonal antibody that selectively targets ICOS ligand (ICOSL), demonstrating synergistic anti-inflammatory effects when used in conjunction with CD28 antibody inhibitors. This antibody is designed for the precise modulation of immune responses, making it a valuable tool for research in immune regulation and potential therapeutic interventions in inflammatory disorders.

The Anti-MUC1/CD227 Antibody (C595 (NCRC48)) is a chimeric mouse monoclonal antibody of the IgG3, κ subclass, specifically designed to target human MUC1/CD227. For accurate experimental control, it is recommended to use Mouse IgG3 kappa as an isotype control. This antibody serves as a crucial tool for the detection and study of MUC1/CD227 expression in various research applications.

Brolucizumab (DLX1008) is a high-affinity single-chain anti-VEGF-A antibody fragment, demonstrating a dissociation constant (K_D) of 1.05 pM. This monoclonal antibody is engineered for precise targeting and inhibition of vascular endothelial growth factor A (VEGF-A), a key molecule involved in angiogenesis. Brolucizumab is utilized primarily in oncological research to study and inhibit tumor-induced blood vessel formation, offering potential insights into cancer therapy mechanisms.

OM-7D3-B3 is a high-affinity monoclonal antibody specifically targeting human claudin-1 (CLDN1) with a dissociation constant (Kd) of 4 nM. This antibody effectively inhibits the role of CLDN1 in facilitating the entry of hepatitis C virus (HCV) into host cells. OM-7D3-B3 is an invaluable tool for advancing research in HCV infection mechanisms and potential therapeutic interventions.

Ligelizumab (QGE 031) is a high-affinity humanized monoclonal antibody targeting immunoglobulin E (IgE). This antibody is specifically designed for the study of chronic spontaneous urticaria, providing a valuable tool for investigating the pathophysiology and therapeutic interventions of this condition.

Suvemcitug is a humanized IgG1κ monoclonal antibody that specifically targets vascular endothelial growth factor (VEGF). This antibody is derived from Oryctolagus cuniculus, commonly known as the African hare. It is designed for use in research applications focused on angiogenesis and vascular biology.

Abciximab (C7E3) is a chimeric monoclonal antibody fragment derived from both mouse and human sources, functioning as an inhibitor of glycoprotein (GP) IIb/IIIa. This agent effectively blocks platelet aggregation and leukocyte adhesion, mechanisms crucial for thrombosis and inflammatory responses, respectively. It achieves its therapeutic effects by targeting and binding to the GP IIb/IIIa receptor, as well as to vitronectin and Mac-1 receptors. This specificity makes Abciximab an essential tool in the study of platelet aggregation pathways and the development of anti-thrombotic therapies.

The Anti-IL-4 Antibody (MP4-25D2) is a chimeric rat IgG1, κ isotype antibody designed to specifically target human Interleukin-4 (IL-4). This antibody is ideal for research focused on the modulation and signaling pathways of IL-4 in immunological responses. For accurate experimental control, it is recommended to use the Rat IgG1 kappa, Isotype Control.

Patritumab is a recombinant human monoclonal antibody that specifically targets ERBB3, exhibiting neutralizing properties. This antibody effectively synergizes with Cetuximab to inhibit the phosphorylation of key signaling proteins including EGFR, HER2, HER3, ERK, and AKT. Through its action, Patritumab induces apoptosis and inhibits tumor growth, demonstrating significant efficacy in preclinical models of pancreatic cancer, non-small cell lung cancer, and colorectal cancer. Patritumab is a valuable tool for research focused on the molecular mechanisms of cancer progression and therapeutic antibody development.

Bexatamig is a bispecific antibody engineered to target IL3RA and NCR1. Its structure comprises a heavy gamma 1 chain variable region and constant region 1 linked to a light kappa chain, further conjugated to the kappa constant region and heavy constant regions 2 and 3. This configuration enables dual specificity, providing a valuable tool for research into the biological pathways and potential therapeutic applications involving these targets.